PLANO, Texas--(BUSINESS WIRE)--VuCOMP, Inc. is pleased to announce the formation of a strategic medical advisory board comprised of breast imaging experts from around the world. The board will leverage their clinical expertise to assist the company with overall product development strategies and enhance VuCOMP’s understanding of the clinical and business challenges facing their customers.
The advisory board will also provide valuable direction as VuCOMP continues to develop a computer-aided detection (CAD) solution for tomosynthesis.
The board is comprised of the following breast imaging experts:
-Debra Copit, MD, FACR, Clinical Associate Professor of Radiology, Jefferson Medical College, Director, Breast Imaging, Albert Einstein, Philadelphia, Pennsylvania
-W. Phil Evans, MD, FACR, Clinical Professor of Radiology, Director of the Center for Breast Care and the George and Carol Poston Professorship in Breast Cancer Research, UT Southwestern, Dallas, TX
-Michael Linver, MD, Director of Mammography, X-Ray Associates of New Mexico, P.C., Clinical Professor of Radiology, University of New Mexico School of Medicine, Albuquerque, New Mexico
-Elizabeth Morris, MD, Chief of Breast Imaging Services, Memorial Sloan-Kettering Cancer Center, New York, NY
-Katja Pinker-Domenig, MD, Chief of the Breast Imaging Section, University of Vienna, Vienna, Austria
-Frank Stöblen, MD, Head of Clinic Gyn. Radiology, Kliniken-Essen Mitte, Essen, Germany
The company expects the board to expand in the coming months to include additional thought leaders with expertise in breast imaging.
“We are pleased to have such an experienced and knowledgeable medical advisory board to help guide VuCOMP in the development of the most effective and clinically relevant products possible,” said VuCOMP President James Pike. “Vital to our success is truly understanding, in great depth, both the clinical needs of our customers, as well as how our products enhance their workflow. Their insights will help us to achieve these objectives.”
To date, VuCOMP has developed and commercialized two breast imaging products, M-Vu® CAD and M-Vu Breast Density. M-Vu CAD received FDA approval for digital mammography in October 2012. While mammography CAD systems have been FDA-approved since 1998, recent FDA guidelines have significantly raised the bar for demonstrating CAD effectiveness, and now recommend comprehensive reader studies proving that radiologists are more effective when they use CAD. The VuCOMP system is the first mammography CAD product in the world to achieve FDA approval under these clinical study guidelines. M-Vu Breast Density received FDA market clearance in December 2013. Both products have been well received by leading radiologists and are in use in clinics around the world. The company has additional products in the development pipeline.
About VuCOMP, Inc.
VuCOMP, Inc. leads the way in setting a new standard for CAD and automated breast density measurement. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.